IE
GTHX

Israel Englander’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Israel Englander’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-13,700
Closed -$312K – 4714
2019
Q3 		$312K Buy
+13,700
New +$432K ﹤0.01% 3547

Other funds holding GTHX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Israel Englander's GTHX Position: Q2 2024 in Review

Israel Englander sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 445,912 shares — an estimated $1.93M sold.

Israel Englander first reported a position in GTHX in Q2 2017 and held it in 20 quarters. The position peaked at $14.6M in Q3 2022. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Israel Englander reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Israel Englander sold 445,912 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $1.93M.
  • Israel Englander first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 20 quarters.
  • Israel Englander's G1 Therapeutics, Inc. Common Stock position peaked at $14.6M in Q3 2022.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.